Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses chemotherapy-induced peripheral neuropathy in breast cancer.
Clinical Pearls
Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses chemotherapy-induced peripheral neuropathy in breast cancer.
- Chemotherapy-induced neuropathy is the most common dose-limiting side effect and there are not any effective therapies for treatment or prevention
- Patients take a variety of supplements or drugs in the hopes that it will help reduce the neuropathy
- Preclinical data has shown that patients who were taking supplements actually had worse neuropathy compared to patients who were taking a placebo
- Researchers analyzed carnitine levels in the blood to ensure that patients took the supplements​
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
